1091 CGC-601, a novel βγ-only IL-2 variant, enhances moderate immune activation without Treg expansion, and exhibits a superior safety evidence in vivo

Abstract

BackgroundIL-2 was first approved by FDA for the solid tumor treatment. However, the therapeutic window of IL-2 (low dose suppresses immune system by Treg activation and high dose represents toxicity)...